新辅助化疗对乳腺癌C-erbB-2、P53、P-gp、GST-π表达的影响  

Effects of neoadjuvant chemotherapy on expression of C-erbB-2,P53,P-gp and GST-π in breast cancer

作　　者：黄建军[1] 杨海松[1] 

机构地区：[1]贵阳医学院附属一医院乳腺外科,贵州贵阳550004

出　　处：《中国现代医学杂志》2011年第2期208-211,共4页China Journal of Modern Medicine

基　　金：贵州省卫生厅基金项目(No:黔卫发[2007]119号)

摘　　要：目的探讨新辅助化疗对乳腺癌C-erbB-2、P53、P-gp、GST-π表达的影响。方法采用免疫组织化学法检测100例乳腺癌新辅助化疗前后C-erbB-2、P53、P-gp、GST-π的表达。结果新辅助化疗前后C-erbB-2、P53表达各有12、17例发生变化,比较差异均无统计学意义;P-gp在化疗前后的阳性表达率分别为41.75%和64.83%,差异有统计意义(P<0.05);GST-π在化疗前后的阳性表达率分别为49.45%和54.94%,差异无统计意义(P>0.05)。结论新辅助化疗能使部分乳腺癌组织中C-erbB-2、P53的表达发生变化,但新辅助化疗对C-erbB-2、P53表达状态无显著影响;新辅助化疗后P-gp表达显著升高,对乳腺癌新辅助化疗有一定预测价值。【Objective】 To study the effect of neoadjuvant chemotherapy on expressions of c-erbB-2,P53,p-gp and GST-π in breast cancer.【Methods】 The expressions of c-erbB-2,P53,P-gp and GST-π in 100 patients with breast cancer were measured by immunohistochemistry before and after neoadjuvant chemotherapy.【Results】 Among all the 100 cases,the status of c-erbB-2 and P53 expressions was changed in 12 and 17 cases respectively,but there was no statistical difference before and after neoadjuvant chemotherapy.The positive expression rates of P-gp before and after chemotherapy were 41.75% and 64.83%,respectively;and their difference was statistically significant（P 0.05）.The expression rates of GST-π before and after chemotherapy were 49.45% and 54.94% respectively,and their difference was not significant（P 0.05）.【Conclusion】 Changes occur in C-erbB-2 and P53 expression after neoadjuvant chemotherapy in patients with breast cancer,but neoadjuvant chemotherapy has no significant influence on status of C-erbB-2 and P53.The expression of P-gp increases significantly after neoadjuvant chemotherapy,which suggests that p-gp could be used to predict the therapeutic efficacy of neoadjuvant chemotherapy.

关 键 词：################ 

分 类 号：R730.53[医药卫生—肿瘤] R737.9[医药卫生—临床医学]